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MaTriglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on
triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower
plasma triglycerides as a means to reduce CVD events. Genetic studies identiﬁed TGRL components and pathways
involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs
contribute to the risk of CVD events. This “omic” approach recently resulted in new targets for reducing CVD
events. (J Am Coll Cardiol 2014;64:2525–40) © 2014 by the American College of Cardiology Foundation.T riglyceride-rich lipoproteins (TGRLs) com-prise a vast array of intestinally derived andhepatically secreted particles with distinct
compositions and associations with risk for cardiovas-
cular disease (CVD) or pancreatitis. Although
the contribution of plasma/serum triglycerides (tria-
cylglycerols [TG]) to increased risk of coronary and ce-
rebrovascular ischemic events was established in
multivariate models that adjust for major risk
markers, including low-density lipoprotein choles-
terol (LDL-C) and high-density lipoprotein cholesterol
(HDL-C) (1,2), elevated TGRLs alter low-density lipo-
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Apo = apolipoprotein
CHD = coronary heart disease
CVD = cardiovascular disease
DGAT = diacylglycerol
acyltransferase
HDL = high-density lipoprotein
LDL = low-density lipoprotein
PPAR = peroxisome
proliferator-activated receptor
TG = triacylglycerols
TGRLs = triglyceride-rich
lipoproteins
VLDL = very low-density
lipoprotein
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2526not only alter TGRL concentration and
composition, but also affect LDL, HDL, and
inﬂammatory pathways.
This state-of-the-art review discusses the
complexities of TGRL-associated atheroscle-
rotic CVD risk and new directions in risk
assessment and therapeutic responses to
TG-lowering therapies from genetic studies.
It is not intended to reiterate recent con-
sensus statements on hypertriglyceridemia
deﬁnitions, diagnosis, and management (4,5).
TGRL, HUMAN ATHEROSCLEROSIS,
AND ATHEROSCLEROTIC
CARDIOVASCULAR EVENTS
Chylomicron and very low-density lipopro-
tein (VLDL) remnants rapidly penetrate the arterial
wall and contribute cholesterol to atherosclerotic le-
sions (6–8). VLDL composition is a critical CVD risk
determinant. In retrospective and prospective popu-
lation studies, TG-associated CHD risk was limited toRAL ILLUSTRATION Intestinal Synthesis and Hepat
Key pathways regulating intestinal synthesis and metabolism of t
of this pathway and its genetic regulation). (Bottom) Key pathw
(see the text for details about this pathway and its genetic regula
¼ diglyceride acyltransferase; ER ¼ endoplasmic reticulum; FA ¼
ylphosphatidylinositol-anchored high-density lipoprotein-binding
otein receptor; LPL ¼ lipoprotein lipase; LRP1 ¼ low-density lipop
lyceride acyl transferase; MTP ¼ microsomal transfer protein; NP
kexin type 9; PCTV ¼ pre-chylomicron transport vesicle; TG ¼ trigl
otein transport vesicle.apolipoprotein (Apo) C3-containing VLDL particles
and their metabolic remnants, small LDL particles (9–
11). VLDL proteome analysis expanded the complex-
ities of VLDL through identiﬁcation of 33 functional
pathways, including 4 related to lipid transport and
lipoprotein metabolism, and 8 associated with coagu-
lation, hemostasis, and immunity (12).
METABOLISM OF INTESTINAL AND
HEPATIC-DERIVED TGRLS
Chylomicrons are intestinal-speciﬁc lipoproteins,
formed mainly in the jejunum after a meal. Owing to
the large TG core (>90%), chylomicron density is
<1.006 g/ml, but they are heterogeneous, ranging from
75 to 1,200 nm in diameter. They also contain a small
amount of cholesteryl esters, 1 structural protein,
apoB48, and minor exchangeable apolipoproteins.
Dietary TG are hydrolyzed in the stomach and
proximal small intestine to form fatty acids and
2-monoacylglycerol (Central Illustration, top) (13).
Enterocytes absorb these lipids through either passiveic Synthesis and Metabolism of TGRLs
riglyceride-rich lipoproteins (TGRLs) are illustrated (see the text for
ays regulating hepatic synthesis and metabolism of TRGLs are illus-
tion). ANGPTL3 ¼ angiopoietin-like protein 3; Apo ¼ apolipoprotein;
fatty acid; HSPG ¼ heparin sulfate proteoglycan; GHIHBP1 ¼
protein 1; LDL ¼ low-density lipoprotein; LDL-R ¼ low-density
rotein receptor-related protein; MG ¼ monoglyceride; MGAT ¼
LC1L1 ¼ Niemann-Pick C1 like; PCSK9 ¼ proprotein convertase sub-
yceride; VLDL ¼ very low-density lipoprotein; VTV ¼ very low-density
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2527diffusion or the action of speciﬁc transporters. At the
endoplasmic reticulum (ER) membrane, mono-
acylglycerol:acyl CoA transferase converts mono-
acylglycerol and fatty acids into diacylglycerol acids,
which diacylglycerol:acyl CoA transferase (DGAT)
subsequently converts into TGs (14). Lipid droplets
(LDs) are transiently formed in the cytosol, and then
fuse with apoB48 phospholipid-rich particles in the
ER lumen via the action of a chaperone, microsomal
transfer protein (MTP), which mediates primordial
chylomicron particle formation. Proprotein con-
vertase subtilisin kexin type 9 (PCSK9) enters and
stimulates intestinal TGRL production by increasing
both apoB48 synthesis and TG production through
transcriptional and post-transcriptional mechanisms
involved in TRL assembly (MTP messenger ribonu-
cleic acid [mRNA], protein, and lipid transfer activity
and Niemann-Pick C1 like protein levels), and sterol
response element binding protein 1 (SREBP1) target
genes involved in fatty acid/triglyceride biosynthetic
pathway (fatty acid synthase, stearoyl-CoA desa-
turases, and diglyceride acyltransferase-2 [DGAT2])
(15). Chylomicrons exit the ER to the Golgi via pre-
chylomicron transport vesicles (16). After a meal,
chylomicrons are exported into mesenteric lymph
before entering the circulation, where they contribute
to post-prandial TG concentrations (17,18). Lipopro-
tein lipase (LPL) subsequently hydrolyzes chylomi-
crons into fatty acids used as an energy supply by the
heart and skeletal muscles or stored in adipose tissue.
Chylomicron remnants are removed from the circu-
lation after binding to the LDL receptor via the apoE
ligand, or by other routes including LDL receptor-
related protein 1 and the heparan sulfate proteogly-
can pathway (19). Although clearance is the primary
mechanism for chylomicron remnants, ApoB48 over-
production increases chylomicron production in
fructose-fed, insulin-resistant hamsters (20).
VLDL biogenesis occurs in hepatocytes by a 2-step
process involving synthesis of partially lipidated
apoB100 to form a primordial VLDL particle (through a
process involving MTP), followed by TG addition to the
primordial particle in the ER lumen (Central Illustration,
bottom). However, apoC3 inhibits VLDL assembly inde-
pendent of MTP (21). After assembly, nascent VLDL par-
ticles are transported to the Golgi by a rate-limiting step
mediatedby a speciﬁc ER-derivedVLDL transport vesicle
(22). Cell death-inducingDFF45-like effector b (cideB) is a
VTF-associated protein that mediates VLDL lipidation
and maturation (23). CideB silencing results in hepatic
secretion of small VLDL particles, which is evidence that
VLDL heterogeneity is, in part, genetically regulated.
LPL is the principal enzyme that hydrolyzes TG
in TGRLs. LPL is primarily synthesized in theparenchyma of tissues that use fatty acids for energy
(cardiac muscle, skeletal muscle) and TG storage (adipose
tissue). LPL attaches to heparan sulﬁde side chains of
proteoglycans, and is transported to the capillary lumen
by the endothelial protein glycosylphosphatidylinositol-
anchored high-density lipoprotein-binding protein-1
(GPIHBP1) (24). GPIHBP1 provides a platform for LPL to
process TG from TGRL. TGRL hydrolysis at the capillary
lumen releases free fatty acids and monoglycerides,
resulting in partially catabolized chylomicrons (chylomi-
cron remnants) and VLDL particles (VLDL remnants).
Due to its critical role in lipid homeostasis, LPL ac-
tivity is highly regulated at the transcriptional, post-
transcriptional, translational, and post-translational
levels. Various proteins regulate LPL including:
apoC1 (25,26), apoC2 (27), apoC3 (26,28), apoA5 (29),
angiopoietin-like protein 3 (ANGPTL3) (30), ANGPTL4
(31,32), and ANGPTL8 (33). ANGPTL4 is a secreted
protein induced in adipose tissue by fasting (34). TGRL
binding stabilizes LPL; however, apoC1 and apoC3
displace LPL from LDs, where ANGPTL4 inactivates it
in the subendothelial space. This allows ANGPTL4 to
bind LPL’s N-terminus, resulting in dissociation of
catalytically active LPL homodimers to monomers
(26). ANGPTL3 renders LPL more susceptible to pro-
teolytic inactivation by proprotein convertases (35).
Low amounts of LPL are detected in human blood,
where it is transported by both apoB48- and apoB100-
containing lipoproteins. In humans, apoB-containing
lipoproteins with LPL are cleared more rapidly than
apoB-containing particles without LPL (36). LPLwasmore
effective in enhancing post-prandial clearance of apoB48-
than apoB100-containing lipoproteins. Although apoE fa-
cilitates receptor-mediated TGRL clearance pathways, it
did not affect TGRL clearance in this study.
The very low-density lipoprotein receptor (VLDLR), an
LDL receptor family member (37), is expressed in heart,
skeletal muscle, and adipose tissue (38,39). Under most
circumstances, it is not detected in the liver; however,
fenoﬁbrate activation of the peroxisome proliferator-
activated receptor (PPAR) alpha increases hepatic VLDLR
translational activity through peroxisome proliferator
response element binding to the VLDL promoter (40).
After VLDLs bind to VLDLR, VLDL-derived FA are deliv-
ered to peripheral tissues, where they are used by heart
and muscle for energy and in adipose tissue as an FA
storage reservoir. ApoC3 impairs VLDL binding to cellular
receptors, resulting in formation of small LDL particles
(10,11), thereby counteracting the effects of apoE (41).
INFLAMMATION
TGRLs produced from both the exogenous (chy-
lomicrons) or endogenous (VLDL) pathways are
TABLE 1
Endotheliu
Blood
Intestinal
microﬂ
AP ¼ activ
proliferator
protein; VCA
VLDL ¼ ver
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2528proinﬂammatory. Chylomicron accumulation favors
pancreatic inﬂammation and is associated with
increased risk of acute pancreatitis. In contrast,
VLDL, intermediate-density lipoprotein (IDL), VLDL
remnants, and chylomicron remnants increase
endothelial inﬂammation and facilitate arterial wall
inﬁltration of monocytes. After a high-fat meal,
hypertriglyceridemic subjects produce large, buoyant
chylomicrons and VLDLs. VLDL particles produced
post-prandially have a distinct fatty acid composition
and increased apoC3 (42,43). TGRLs with high TG
content up-regulate tumor necrosis factor-alpha,
thereby inducing vascular cell adhesion molecule
(VCAM)-1 expression in human aortic endothelial cells
and monocyte adhesion. By reducing VCAM-1 expres-
sion and monocyte recruitment, TGRLs with low
triglyceride content have an atheroprotective effect
(42–44) (Table 1). The inﬂuence of TGRLs on VCAM-1
transcription and expression depends on ER homeo-
stasis. ER stress is the accumulation of unfolded or
misfolded proteins in the ER lumen, and is a unifying
moniker for metabolic dysregulation linking obesity to
insulin resistance and inﬂammation in diabetes and
atherosclerosis (45,46). ER stress is mitigated by the
unfolded protein response, which involves dissocia-
tion of binding immunoglobulin protein from ER
transmembrane sensor proteins and their downstream
effectors. In hypertriglyceridemic subjects, TGRLs
regulate tumor necrosis factor alpha–induced VCAM-1
expression kinetics through processes involving ER
stress and the unfolded protein response (47).
TGRL lipolysis by LPL on the endothelial cell sur-
face elaborates high concentrations of lipolysis prod-
ucts along the blood endothelial interface, which may
contribute to atherosclerosis through mechanisms
encompassing proinﬂammatory, procoagulant, and
proapoptotic gene activation. TGRL lipolysis releases
neutral and oxidized free fatty acids that induce
endothelial inﬂammation, vascular apoptosis (48),
and reactive oxygen species production in endothe-
lial cells, and altered lipid raft physiology (49).TGRLs and Inﬂammation
m VCAM-1 transcription and expression
Monocyte inﬁltration
Increased permeability facilitates VLDL remnant uptake
Lipolytic products (oxidized fatty acids)
ROS-mediated AP-1 up-regulation of IL-1, IL-6, IL-8, VEGF,
and PPAR-gamma
ora
LPS transport into blood via dietary lipids
ator protein; IL ¼ interleukin; LPS ¼ lipopolysaccharide; PPAR ¼ peroxisome
-activated receptor; ROS ¼ reactive oxygen species; TGRL ¼ triglyceride-rich lipo-
M ¼ vascular cell adhesion molecule; VEGF ¼ vascular endothelial cell growth factor;
y low-density lipoprotein.The mechanism for vascular inﬂammation and
apoptosis depends upon induction of transcription
factor ATF3-related genes in p38 and stress-activated
protein kinase/c-Jun N-terminal kinase subset of
mitogen-activated protein kinase signaling, and
cytokines associated with activator protein 1 sig-
naling, including interleukin-1-alpha, interleukin-6,
interleukin-8, vascular endothelial cell growth fac-
tor, and PPAR-gamma (50). TGRL lipolysis products
increase endothelial permeability and VLDL remnant
uptake in the artery wall (51). The presence of VLDLR
on macrophages, endothelium, and vascular smooth
muscle surfaces of the vessel wall may further facili-
tate internalization of VLDL remnants.
Intestinal microﬂora were recently recognized as
another source of inﬂammatory mediators. Gram-
negative bacteria in the intestinal microﬂora release
lipopolysaccharide (LPS) after lysis. Dietary lipids
facilitate LPS entry into the circulation (52). Upon cell
entry via Toll-like receptor 4, LPS activates redox-
sensitive transcription factors that regulate proin-
ﬂammatory responses.
TGRLs increase atherosclerosis, inﬂammation, and
the lipid content of atherosclerotic lesions both
directly and indirectly. Causal pathways supporting
direct contributions of TGRLs to CVD events are dis-
cussed in the following sections.
PHYSIOLOGY OF POST-PRANDIAL LIPEMIA:
CARDIOVASCULAR RISK OF FASTING
VERSUS NONFASTING TRIGLYCERIDE
MEASUREMENT
Current guidelines recommend screening and man-
agement of patients with hypertriglyceridemia on the
basis of fasting TG measurement (53,54). However,
prospective studies suggest that altered post-prandial
TG metabolism contributes to atherosclerosis and
may predict CVD development. Furthermore, studies
demonstrated variable post-prandial metabolic re-
sponses in dyslipidemic patients compared with
healthy subjects, suggesting that common genetic
polymorphisms may underlie this difference (55,56).
Nonfasting TG measurement was proposed as a
marker for CVD risk stratiﬁcation; however, further
investigation into factors modulating the post-
prandial response may prove valuable.
The recommendation for TG measurement in the
fasting state arose due to early work demonstrating
the unreliability of fat tolerance testing, primarily
due to individual differences in gastric emptying,
raising concerns regarding serum TG level variability
(57–59). The lack of direct LDL-C assays promoted
widespread adoption of the Friedewald equation to
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2529estimate LDL-C, which depends on fasting-state
measurements (60). Additionally, epidemiological
evidence showed that fasting TGs are statistically
independent predictors of atherosclerosis and inci-
dent CVD events (1,2). Studies also revealed a strong
correlation between fasting and nonfasting TG,
regardless of glucose status. Thus, fasting TG levels
have been used as a predictor of post-prandial TG
levels (61,62). However, the recommendation to
measure fasting TG is not made on the basis of pro-
spective studies demonstrating its superiority in
predicting CVD risk compared with nonfasting TG.
Instead, following the implementation of screening
guidelines, epidemiologic investigations simply
adopted fasting TG level measurements (62).
In contrast to the observed variability with fat
tolerance tests, lipoprotein proﬁles change only
minimally in response to normal food consumption in
healthy individuals, thereby calling into question
concerns over post-prandial serum TG level variability
(60,62). In addition, fasting TG measurement may not
accurately capture the effect of TGRLs and remnant
particles in the post-prandial period on multiple li-
poprotein proﬁle components (63). Furthermore,
prospective studies suggested that nonfasting TG
levels are equal to or, in some populations, better than
fasting TG levels for predicting future CVD eventsTABLE 2 Recent Studies Investigating the Use of Nonfasting TG and
Study/First Author (Ref. #)
Primary Endpoint,
Sample Size
Primary Endpoin
Hazard Ratio (95%
The Women’s Health
Study (64)
Incident CVD, nonfatal
MI, nonfatal stroke,
coronary
revascularization, or
cardiovascular death
(n ¼ 26,509)
Fasting
2.23 (1.82–2.74
Nonfasting
2.53 (1.69–3.79
Nordestgaard et al. (65) Incident MI, CVD, and death
with 1 mmol/l increase in
nonfasting TG
(n ¼ 13,981)
CVD outcome
Women
1.30 (1.22–1.40
Men
1.14 (1.10–1.19
Varbo et al. (72) Incidence of CVD with 1
mmol/l increase in
nonfasting RC
(n ¼ 73,513)
1.4 (1.3–1.5)
Jørgensen et al. (73) Incidence of MI with
genetically elevated
doubling of nonfasting TG
and RC (n ¼ 10,391)
1.87 (1.25–2.81
1 mmol/l ¼ 88.41 mg/dl.
CCHS ¼ Copenhagen City Heart Study; CGPS ¼ Copenhagen General Population Study;
FTT ¼ fat tolerance test; HDL-C ¼ high-density lipoprotein cholesterol, LDL-C ¼ low
TG ¼ triglycerides.(64,65). These studies controlled for variability in
post-prandial TG measures by stratifying by time
since last meal, in addition to other factors implicated
in affecting post-prandial measures including age,
sex, body mass index, ethnicity, menopausal status,
hormone use, and diabetes (64,65) (Table 2).
The post-prandial period is characterized by
circulation of potentially atherogenic lipoprotein
particles absorbed and processed through the
intestine and liver, including chylomicrons, VLDL,
and remnant particles (55,66). Their presence is
modulated by traditional epidemiologic and environ-
mental factors including sex, age, body mass index,
physical activity, and smoking, and by the amount
and type of dietary fat in a meal (67,68). Because in-
dividuals are in the nonfasting state most of the day
(approximately 18 h) (68), the notion that alterations
in post-prandial TG concentration and lipoprotein
clearance contribute to atherogenesis is plausible.
Recent data showed that in normolipidemic control
subjects, a post-prandial rise in TG and quantitative
changes in other lipoproteins and lipids are negligible
in response to dietary fat compared with baseline
values (58). However, in patients with dyslipidemia,
the rise in TGRL is 3-fold greater than normal, and
persists for up to 8 h (55,56). Studies demonstrated the
atherogenic potential of remnant particles in theseRC Levels as Predictors of CVD Events
t,
CI)
Subgroup,
Sample Size
Subgroup
Primary Endpoint,
Hazard Ratio (95% CI)
Fasting/Nonfasting Deﬁnition
(Limitations)
)
)
HDL-C $50 mg/dl Fasting
1.32 (1.03–1.68)
Nonfasting
1.94 (1.21–3.10)
Fasting: $8 h since last meal
Nonfasting: <8 h since last meal
(Only 1 measurement collected from each
subject—either a fasting or nonfasting
measurement, as determined by self-
reporting of time from last meal)
:
)
)
Adjusted for baseline
HDL-C
Women
1.25 (1.14–1.37)
Men
1.12 (1.07–1.18)
Fasting: No fasting samples collected
Nonfasting: 1–8 h from last reported meal
(Nonfasting group consisted of post-prandial
measures from subjects within the CCHS
and CGPS, and therefore across different
time periods and by different methods
[self-report and FTT])
Adjusted by ratio of
nonfasting RC to
HDL-C
1.23 (1.19–1.27) Fasting: No fasting samples collected
(Nonfasting RC calculated indirectly by
subtracting HDL-C and LDL-C from TC)
) Adjustment by
nonfasting
measure
TG
1.57 (1.32–2.68)
RC
1.67 (1.38–2.02)
(Nonfasting group consisted of post-prandial
measures from subjects within the CCHS,
CGPS, and CIHDS, and therefore with
methodological variability in collecting
nonfasting TG levels [adjusted for in the
Jørgensen et al. (73) study])
CI ¼ conﬁdence interval; CIHDS ¼ Copenhagen Ischemic Heart Disease Study; CVD ¼ cardiovascular disease events;
-density lipoprotein cholesterol; MI ¼ myocardial infarction; RC ¼ remnant cholesterol; TC ¼ total cholesterol;
FIGURE 1 Effect o
In patients with incre
(VLDL) is secreted w
triglyceride-rich lipop
dense low-density li
cholesterol (HDL-C).
HL ¼ hepatic lipase;
high-density lipopro
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2530patients, including chylomicron remnants, not previ-
ously known to be proatherogenic (69–73); this
likely explains the strength of nonfasting TG mea-
surements in identifying patients at greater CVD risk.
Post-prandial TG metabolism abnormalities are
also strongly associated with single nucleotide poly-
morphisms (SNPs) at common genetic loci, suggesting
genetic mediation of interindividual variation in
post-prandial lipemia (5,70). These associations
persist after accounting for effects on other lipid
traits, including LDL-C, HDL-C, and lipoprotein con-
centrations. Among the >150 deoxyribonucleic acid
(DNA) sequence variants associated with serum
lipids, candidate genes associated with post-prandial
lipemia include apolipoprotein genes A1, A4, A5, C3,
and E, as well as LPL, fatty acid binding protein 2,
MTP, and scavenger receptor B1 (74). The ApoA5 locus
has the strongest causal association between non-
fasting TG and incident CVD (73,74).
ApoA5 is involved in multiple stages of TGRL
metabolism, including VLDL production, TGRL
remnant clearance, and regulation of LPL activity (3).
Early studies of apoA5 knockout mice reported a
400% increase in serum TG levels (73,75,76). Genome-
wide association studies (GWAS) reliably demon-
strated that polymorphisms in or near the apoA5f apoC3 on VLDL Metabolism
ased hepatic lipogenesis, enlarged very low-density lipoprotein
ith apolipoprotein (apo)C3. ApoC3 slows clearance of these
roteins (TGRLs), resulting in increased remnant cholesterol and small
poprotein cholesterol (LDL-C), and low high-density lipoprotein
CE ¼ cholesterol ester; CETP ¼ cholesterol ester transfer protein;
LDL ¼ low-density lipoprotein; LPL ¼ lipoprotein lipase; sHDL ¼ small
tein; TG ¼ triglyceride.locus are associated with nonfasting TG levels.
Furthermore, associations between apoA5 genetic
variants and incident CHD in direct relation to the
increase in elevated nonfasting TG and remnant
cholesterol were recently reported (76–78). In-
vestigations into the additive effect of other SNPs,
including glucokinase regulatory protein, apoE, and
LPL, further enhanced the predictive ability of SNP-
phenotype associations (67,74). Similarly, environ-
mental factors, such as obesity, modify the effect of
the apoA5 locus on post-prandial TGRL metabolism
and atherosclerosis (77). Other studies demonstrated
differential post-prandial responses to therapy on the
basis of genetic variants at this locus, suggesting that
SNP alterations may predict treatment efﬁcacy (78).
Other gene loci thought to be important regulators
of the TG response to dietary fat consumption were
reported, including ANGPTL4 and PPAR alpha (67,74).
With increasing appreciation of nonfasting TG levels
and CVD risk, further investigation into the roles of
genetic variants and environmental factors in medi-
ating the post-prandial response may provide prom-
ising therapeutic approaches.
ATHEROGENICITY OF TGRL CHOLESTEROL
Non–HDL-C is an aggregate measure of the choles-
terol content transported in atherogenic lipoproteins.
The greater predictive value of non–HDL-C over LDL-
C comes from the premise that VLDL-C (non–HDL-C
minus directly-measured LDL-C, also known as
remnant cholesterol or TGRL cholesterol) is also
atherogenic. Recent data supports the hypothesis
that VLDL-C or remnant cholesterol is even more
atherogenic than LDL-C. Remnants can cross the
endothelial barrier and were identiﬁed in human
arteries (79). Because of their larger size, TGRL carries
5 to 20 times more cholesterol/particle than LDL.
Importantly, unlike native LDL, remnants can be
taken up in an unregulated fashion by scavenger re-
ceptors expressed by resident macrophages in the
subendothelial space, thus promoting foam
cell formation. Chylomicron remnants and VLDL
remnants rapidly penetrate the arterial wall and
contribute to atherogenesis (6,8). VLDL composition
is also a critical CVD risk determinant. In retrospective
and prospective population studies, TG-associated
CHD risk was limited to apoC3-containing VLDL par-
ticles and their metabolic remnants, small LDL parti-
cles (9–11). ApoC3 impairs VLDL binding to cellular
receptors, resulting in small dense LDL particle for-
mation (9,10), thereby counteracting the effects of
apoE (11) (Figure 1). In 2 prospective cohorts, the
Nurses’ Health Study and the Health Professionals
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2531Follow-up Study, CHD risk was higher in VLDL and
LDL with apoC3 with a low apoE content than with a
high apoE content (multivariable-adjusted relative
risk for apoE content in LDL with apoC3 for the top vs.
lowest quintile: 0.45, 95% conﬁdence interval [CI]:
0.31 to 0.64; and for VLDL with apoC3: 0.50, 95% CI:
0.35 to 0.72; p value for trend <0.001) (11).
More recently, a Mendelian randomization study
supports a causative role for remnant cholesterol in
CHD (72) (Table 2). In this study, a small number of
SNPs were strongly associated with remnant choles-
terol, remnant cholesterol/HDL-C, LDL-C, and HDL-C.
Notably, risk alleles for remnant cholesterol, remnant
cholesterol/HDL-C, and LDL-C were even more
strongly associated with CHD risk than measured
lipid levels. Remnant cholesterol was more strongly
linked to CHD than LDL-C (hazard ratio [HR]: 2.82 for
remnant cholesterol vs. 1.41 for LDL-C). This concurs
with previous genetic studies and likely relates to the
genetic determinants of a lipid/lipoprotein trait more
accurately representing a subject’s lifetime exposure
than a single biochemical measure. In contrast, the
number of risk alleles for reduced HDL-C showed
no relationship to CVD events. The strength of
this analysis includes large datasets, consisting of
>73,000 Copenhagen participants enrolled in 1 of 2
prospective studies (72), or a case-control study with
a total of nearly 14,000 diagnosed with CHD (65).
NON-HDL-C, APOLIPOPROTEIN B, AND
LDL PARTICLE CONCENTRATION AS
TARGETS OF THERAPY FOR THE
PREVENTION OF ATHEROSCLEROSIS AND
ATHEROSCLEROTIC CVD
Hypertriglyceridemia is accompanied by elevated
non–HDL-C levels (due to increased VLDL-C), IDL,
small and total LDL particles, and total apoC3, as well
as decreased HDL-C levels due to fewer smaller HDL
particles. All of these changes are associated with
increased risk, and which parameters are causal is
debated. Population studies consistently show that
non–HDL-C more strongly correlates with CHD event
risk than LDL-C in those with and without hyper-
triglyceridemia (80). A large meta-analysis of statin
outcome trials found that the subgroup of patients on
statin therapy with non–HDL-C >130 mg/dl and with
LDL-C >100 mg/dl had the highest relative risk (HR:
1.32) compared with patients with both LDL-C and
non–HDL-C at the target levels of <100 and <130
mg/dl, respectively. The view expressed in the Na-
tional Cholesterol Education Program Adult Treat-
ment Panel III report is that TGRLs (remnants
of VLDL, IDL, and chylomicron particles) areatherogenic, and that VLDL-C is a strong correlate of
TGRL cholesterol (81). Thus, non–HDL-C is a better
indicator of the total cholesterol burden carried by
atherogenic lipoproteins (“real” LDL þ IDL þ Lp(a) þ
VLDL þ chylomicron remnants). Although the Amer-
ican College of Cardiology/American Heart Associa-
tion cholesterol guidelines did not recommend non–
HDL-C as a therapeutic target, as it was not a primary
efﬁcacy measure in clinical trials of statin therapy (82),
a meta-analysis of randomized placebo or active-
controlled trials showed that non–HDL-C reduction
was associatedwith a reduction in nonfatalmyocardial
infarction and CHD death (83).
The superiority of non–HDL-C as a biomarker of
risk was suggested to not result from TGRL athero-
genicity, but to instead reﬂect the relationship
between non–HDL-C and the number of circulating
LDL particles (84). The basis for this argument is
that whether or not an individual has hyper-
triglyceridemia, approximately 90% of apoB is found
in LDL particles. In those with an elevated TG con-
centration, the average LDL particle size is typically
smaller, and thus the LDL particle concentration is
often higher than would be predicted from the LDL-C
level. In the ARIC (Atherosclerosis Risk in Commu-
nities) study, small, dense LDL-C was associated with
incident CHD (85). In a GWAS performed in the ARIC
study, the PCSK7 locus was associated with small,
dense LDL-C, suggesting that genetic variants
contribute to CHD risk. However, in a prospective
study that adjusted for the risk of small LDL versus
large LDL particles per total LDL particle concentra-
tion, risk relationships for incident CVD were not
signiﬁcantly higher for small LDL particles (86).
In studies including higher proportions of in-
dividuals with insulin resistance (obesity, metabolic
syndrome, and type 2 diabetes), the discordance
between LDL-C and total and small LDL particles
increases. After multivariate adjustment, including
major CHD risk factors, TG, and HDL-C, LDL particles
are associated with a 2-fold higher risk of atheroscle-
rosis andCVDevents (reviewed inRosenson et al. [87]).
These prospective studies were the basis for multiple
professional society recommendations for a hierar-
chical approach emphasizing LDL-C, non–HDL-C,
and apoB/LDL particles for evaluation of CVD risk
(88–91).
Controversy exists regarding whether there is
an atherogenicity gradient across apoB-containing
lipoproteins and, if so, whether it is incremental,
particularly in the general population or in sub-
populations with low insulin resistance rates (80).
Most dyslipidemia guidelines recognize LDL-C as the
major atherogenic lipoprotein and the primary target
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indicate that that VLDL is at least as (or more)
atherogenic than LDL (73,79). Thus, according to
recent professional society guidelines, combining
LDL-C and VLDL-C makes non–HDL-C a preferred
target in patients with dyslipidemia (93,94). More-
over, a recent analysis of contemporary statin trials
demonstrated that on-treatment levels of non–HDL-C
are more strongly associated with future risk of CVD
events than either apoB or LDL-C (80). In the same
analysis, non–HDL-C explained a larger proportion of
the atheroprotective effects of statin therapy than
either apoB or LDL-C. These ﬁndings favor the use of
non–HDL-C over LDL-C as a therapy target, particu-
larly in hypertriglyceridemic individuals (93,94).
Since apoB is the major apolipoprotein of both LDL
and VLDL, some investigators propose total apoB as
an alternative to non–HDL-C (95).
TGRLS: LESSONS FROM HUMAN GENETICS
Over the past 15 years, human genetic studies have
identiﬁed new proteins involved in TGRL meta-
bolism, revealed insights into the genetic architec-
ture of plasma TG, and clariﬁed the contribution of
TGRL to human CVD. At least 3 different human
genetic approaches—sequencing of biologic candidate
genes, genetic analysis of Mendelian TG phenotypes,
and GWAS of common DNA sequence variants—have
yielded new proteins and novel human DNA variants
involved in plasma TGRL regulation. Notable exam-
ples include apoA5 (biologic candidate), ANGPTL3
(biologic candidate and Mendelian low TG), LMF1
(biologic candidate), apoC3 (GWAS), GCKR (GWAS),
COL18A1 (GWAS), and TRIB1 (GWAS), among many
others (96–106).
The genetic architecture for TG in the popula-
tion appears to be a mosaic comprised of rare large-
effect variants, common small-effect variants, andTABLE 3 DNA Sequence Variants in LPL-Regulating Genes Associated
Gene rsID Protein
Effect of
Variant on
Protein Function
Effect
Mutatio
LPL Act
LPL rs1801177
rs328
D36N
S474X
Loss
Gain
Decre
Increa
APOA5 rs662799 Promoter
-1131T/C
Loss Decre
ANGPTL4 rs116843064 E40K, T266M Loss Increa
APOC3 multiple R19X, IVS2þ1 G/A,
IVS3þ1 G/T, A43T
Loss Increa
CHD ¼ coronary heart disease; LPL ¼ lipoprotein lipase; TG ¼ triglycerides.environmental inﬂuences (107). Variants associated
with common, complex traits like plasma TG range
from common (>1:20) frequency to low frequency
(1:200 to 1:20) and to rare (<1:200). Roughly 50% of
interindividual plasma TG variability is estimated to
come from DNA sequence variants. Johansen et al.
(108) studied individuals from the extremes of the
plasma TG distribution (438 individuals with high TG
[mean 1,255 mg/dl] and 327 individuals with low TG
[mean 106 mg/dl]) using both GWAS and resequenc-
ing of selected genes. In the GWAS, common variants
at 7 loci were associated with plasma TG, and there
was an excess of rare, nonsynonymous variants
across 4 genes in individuals with high TG compared
with those with low TG in the resequencing study. A
comprehensive logistic regression model including
clinical variables and both common and rare genetic
variants explained 42% of total variation in hyper-
triglyceridemia diagnosis: clinical variables explained
20%, common genetic variants in 7 loci explained
21%, and rare genetic variants in 4 loci explained 1%.
Genetics can be used to distinguish causal from
reactive processes in humans, and such studies
have suggested that plasma TG causally relates to
CHD. A common polymorphism in the APOA5 gene’s
promoter region led to decreased gene expression
and was not only associated with higher plasma TG,
but also with higher CHD risk (3). GWAS deﬁned >150
polymorphisms associated with plasma lipids (102).
Across 185 polymorphisms, the strength of a variant’s
effect on plasma TG highly correlated with the
magnitude of its effect on CHD, even after accounting
for each variant’s potential effects on LDL-C and/or
HDL-C (109). These results support the notion that
TGRL causally inﬂuences CHD risk.
Common, low frequency, and/or rare DNA
sequence variants in 4 TGRL metabolism genes were
convincingly associated with CHD risk, and all 4
genes functionally relate to LPL (Table 3). BeyondWith TG and CHD
of
n on
ivity
Lipid
Phenotype
Association
CHD
Risk
Allele
Frequency
in Whites
Allele
Frequency
in Blacks Ref. #
ase
se
[TG
YTG
[
Y
2%
11%
5%
7%
(72)
ase [TG [ 8% Rare (3)
se YTG Y 1.6% 0.1% (96)
se YTG Y 0.7%
(collective for all
4 mutations)
0.7%
(collective for all
4 mutations)
(99,110,111)
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functionally related genes where naturally occurring
genetic variation alters the complex disease of CHD.
We highlight 2 recent studies that establish a central
role of apoC3 in TG and CHD risk (110,111). In the ﬁrst
study (110), the protein-coding regions (exome) of
18,666 genes were sequenced in 3,734 individuals
from the United States, and rare mutations in each
gene were tested for association with plasma TG. The
top result was for APOC3. Approximately 1 in 150 in-
dividuals carried any of 4 protein-altering or splice-
site variants of APOC3. Heterozygous carriers of any
of these 4 APOC3 mutations had 39% lower plasma TG
(p < 1  1020), 46% lower circulating plasma APOC3
(p ¼ 8  1010), and 40% lower risk for CHD (odds
ratio: 0.60, 95% CI: 0.47 to 0.75; p ¼ 4  106).
A second study (111), using data from 75,725 par-
ticipants in 2 general population studies in Denmark,
associated low levels of nonfasting TG with reduced
risks of ischemic vascular disease and ischemic heart
disease. Participants with nonfasting TG levels <90
mg/dl had a signiﬁcantly lower incidence of CVD than
those with levels $350 mg/dl (HR for ischemic
vascular disease: 0.43, 95% CI: 0.35 to 0.54; HR for
ischemic heart disease: 0.40, 95% CI: 0.31 to 0.52).
Sequencing of APOC3 in 10,797 participants identiﬁed
3 of the 4 loss-of-function mutations from the ﬁrst
study. Those heterozygous for loss-of-function
mutations in APOC3 had lower TG and lower is-
chemic vascular disease risk, at estimates remarkably
similar to the ﬁrst study (44% nonfasting TG and 41%
for ischemic vascular disease) (99). Findings from
these 2 studies extend a previous observation that the
APOC3 R19X mutation was quite frequent (5%) in the
Amish population and associated with lower plasma
TG and decreased coronary artery calcium (99). These
human genetic data suggest that therapeutic strate-
gies that enhance LPL function, decrease APOC3
function, decrease ANGPTL4 function, or enhance
APOA5 function should be cardioprotective.
RECENT ADVANCES IN THE GENETICS AND
THERAPEUTIC BENEFITS OF CURRENTLY
AVAILABLE TG-LOWERING DRUGS
Four classes of agents are currently available for
managing hypertriglyceridemia: ﬁbrates (PPAR-alpha
agonists); niacin; omega-3 fatty acids; and medium
chain triglyceride (MCT) oil, the latter being mainly
used for treatment of chylomicronemia andMendelian
forms of severe hypertriglyceridemia (TG >1,000
mg/dl). Although not TG-lowering agents, statins
reduce TG in patients with mild to severe hyper-
triglyceridemia, and the more effective the statin indecreasing LDL-C, the greater its effect on plasma TG
(112). Pooled data from placebo-controlled trials also
suggest that 2 to 7 years of statin treatmentmay reduce
the risk of pancreatitis in patients with mild to mod-
erate hypertriglyceridemia. However, because severe
hypertriglyceridemia is clinically, physiologically, and
metabolically distinct from mild to moderate hyper-
triglyceridemia (5,113), statins have limited efﬁcacy for
management of severe hypertriglyceridemia and the
clearance of large, buoyant, TG-rich lipoproteins such
as chylomicrons. When the fasting TG concentration is
>1,000 mg/dl, chylomicrons are the predominant
plasma lipoproteins. At TG levels between 500 and
1,000 mg/dl, chylomicrons, VLDL, and remnant lipo-
proteins cohabit in variable proportions, whereas
minimal fasting chylomicronemia is observed when
TG values are <500 mg/dl. The pancreatitis risk is
highest in the presence of severe hypertriglyceridemia
and chylomicronemia (5,113).
The physiology of hypertriglyceridemia is com-
plex, involving exogenous and endogenous metabolic
pathways for 2 distinct lipoproteins and a variety of
mechanisms and tissues. Consequently, it is not sur-
prising that most currently available TG-lowering
agents, almost all of which inﬂuence expression of
key lipid metabolism genes, have pleiotropic effects
and act on multiple targets. Changes in gene expres-
sion induced by TG-lowering drugs contribute to their
efﬁcacy, or may exacerbate side effects that limit their
therapeutic use. For example, fenoﬁbrate exerts its
beneﬁcial hypotriglyceridemic action by activation
of PPAR alpha, a nuclear receptor protein that in-
creases the gene transcription, expression, and ac-
tivity of LPL and apoAI, among others (114,115).
Recent genetic analyses in mice suggest that fenoﬁ-
brate may increase the risk of hepatic steatosis in
a dose-dependent manner by acting on the expres-
sion of genes associated with lipogenesis and by
up-regulating SREBP-1c (116). However, the effect of
PPAR alpha agonists on liver steatosis remains
controversial (117). In contrast, recent data suggest
that niacin has no effect on SREBP-1c mRNA expres-
sion but signiﬁcantly inhibits DGAT-2 mRNA levels,
protein expression, and activity, thereby signiﬁcantly
regressing hepatic steatosis in rats with pre-existing
steatosis (118). However, high-dose niacin has multi-
ple side effects in humans, including possible induc-
tion of chemical hepatitis. Niacin up-regulates a
niacin receptor 1 (GPR109A) genetic cascade, which
activates arrestin beta 1–mediated ERK1/2 MAP kinase
and prostaglandin D2 release, and (depending on
the drug formulation) causes ﬂushing that often
limits niacin use. Sustained-release niacin is generally
better tolerated, but is more hepatotoxic than
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Study-2 and AIM-HIGH (Atherothrombosis Interven-
tion in Metabolic Syndrome with Low HDL/High Tri-
glycerides: Impact on Global Health Outcomes) trials,
extended-release niacin was associated with in-
creased infection rates (119,120).
OMEGA-3S FOR MANAGEMENT OF
HYPERTRIGLYCERIDEMIA
Since the initial observations by Bang et al. (121) in the
early 1970s that Greenland Eskimos with a diet rich in
omega-3 fatty acids have a low incidence of CVD,
clinical beneﬁts of the major omega-3 fatty acids,
eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) have been investigated extensively. There
is a better understanding that the complex mixture of
fatty acids found in ﬁsh oil contains multiple active
components, and that each of the major omega-3 fatty
acids (EPA, DHA, and docosapentaenoic acid [DPA]),
has overlapping, but distinct, biological activities
(122). Health beneﬁts of omega-3 fatty acids are linked
to ﬁsh intake, but EPA, DHA, and DPA plasma levels
are also determined by polymorphisms of the desa-
turases (delta-5 and -6) that convert short-chain
polyunsaturated fatty acids (SC-PUFAs) to long-
chain polyunsaturated fatty acids (LC-PUFAs). Not
only has the role of omega-3 fatty acids in human
health broadened since the initial observations in
Greenland Eskimos, but there is also a better appre-
ciation of the pharmacological and biological in-
tricacies of the major fatty acid constituents of ﬁsh
oil.
Recent advances in “omics” suggest new mecha-
nisms of action for niacin and omega-3 fatty acids
(123–129). Clinical trials conducted with GPR109A ag-
onists, studies in mice lacking GPR109A, and analyses
of niacin’s effect on gene expression proﬁles in skel-
etal muscle of obese Zucker rats suggest that niacin’s
mechanism of action is not mainly driven by adipo-
cyte triglyceride lipolysis, but involves genes and
consecutive metabolic effects in hepatocytes, skeletal
muscle cells, macrophages, neutrophils, and the
endothelial wall (123–125).
Omega-3 fatty acids modify expression of acylgly-
cerol synthesis pathway genes and their poly-
morphisms (particularly GPAM, AGPAT3, and
AGPAT4) modulate the effect of omega-3 fatty acids
on plasma TG concentration (126). The EVOLVE
(Epanova for Lowering Very High Triglycerides) clin-
ical trial (127), demonstrated the safety and efﬁcacy of
the free fatty acid form of omega-3 fatty acids
in severe hypertriglyceridemia (plasma TG concen-
tration from 500 to 2,000 mg/dl), conﬁrming thatthey are effective on post-prandial metabolism and
the exogenous (chylomicron-dependent) metabolic
pathway. A recent study suggests that the biologic
effect of omega-3 fatty acids in enterocytes may be
exerted through microribonucleic acids (miRNAs),
particularly miR-192 and miR-30c. miRNAs are small,
noncoding RNA molecules that play key roles in
transcriptional and post-transcriptional regulation of
gene expression. Enterocyte targets of miR-192 and
miR-30c include genes encoding nuclear receptor
corepressor 2, isocitrate dehydrogenase 1, caveolin 1,
ATP-binding cassette subfamily G member 4, and
retinoic acid receptor b (128).
FADS POLYMORPHISMS AND PLASMA LEVELS
OF OMEGA-3 FATTY ACIDS
Until recently, dietary intake of long-chain marine
omega-3 fatty acids was thought to be the major
determinant of plasma concentrations. Short-chain
omega-3 fatty acids, primarily alpha-linolenic acid,
are abundant in the diet, but only small amounts are
converted to EPA and even less are elongated to DHA
by desaturase enzymes (delta-5 and -6) (Figure 2A)
(129). However, it is now widely recognized that
genetic polymorphisms of the desaturase genes,
FADS1 to 3, signiﬁcantly affect LC-PUFA formation.
FADS polymorphisms are relatively common and
potent, and may explain up to 30% of the variability in
LC-PUFA levels (both omega-6 and -3). For example,
about 80% of African Americans have a polymorphism
(rs174537) associated with more effective conversion
of SC-PUFA to LC-PUFA by desaturase-5, resulting in
higher levels of both arachidonic acid (AA) and EPA,
even though their ﬁsh consumption is lower, on
average, than that of whites. The “desaturase hy-
pothesis” (130) is that, in populations following a
Western diet rich in omega-6 and relatively deﬁcient
in omega-3 PUFAs, FADS polymorphisms associated
with high desaturase activity may lead to predominant
proinﬂammatory, detrimental effects (131). It is
intriguing to hypothesize that the higher levels of
disorders such as hypertension, asthma, and aspirin
resistance in African Americans are linked to a higher
inﬂammatory state driven by overproduction of pros-
taglandins and leukotrienes synthesized from AA. In
contrast, Hispanic individuals more commonly have a
different FADS polymorphism (rs17454), resulting in
less conversion of SC-PUFA to LC-PUFA, and they
consequently have lower AA and EPA levels (130,132).
This FADS polymorphism is associated with dyslipi-
demia (high TG and HDL-C), modulated, in part, by
PUFA intake. This polymorphismmay explain the high
prevalence of hypertriglyceridemia in the Hispanic
FIGURE 2 FADS Polymorphisms and Fatty Acid Metabolism
(A) Long-chain polyunsaturated fatty acid (PUFA) plasma levels are determined by both
dietary intake and conversion of shorter-chain PUFAs by the delta-5 and -6 desaturases.
Polymorphisms of these fatty acid desaturases (FADS) result in either higher or lower long-
chain PUFA levels, possibly explaining differences in hypertriglyceridemia prevalence
between Hispanics and African Americans. (B) Long-chain omega-3 fatty acids in ﬁsh oils
decreasehepatic lipogenesis, thereby reducingVLDL-c levels, and enhance the conversionby
LPL of VLDL to LDL mediated in part by a decrease in apoC3. AA ¼ arachidonic acid;
ALA ¼ alpha-linoleic acid; CHD ¼ coronary heart disease; DGLA ¼ dihomo-gamma-linoleic
acid; DHA ¼ docosahexaenoic acid; DPA ¼ docosapentaenoic acid; EPA ¼ eicosapentaenoic
acid; GLA ¼ gamma-linoleic acid; LA ¼ linoleic acid; other abbreviations as in Figure 1.
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dominantly in African Americans and associated with
higher EPA levels may lead to their lower incidence of
elevated TG and higher HDL-C levels. Further studies
are needed to deﬁne the function of FADS1 and FADS2
polymorphisms relative to mechanisms involved in
the development of atherosclerosis, dyslipidemia, and
other diseases linked to either AA overproduction or
marine LC-PUFA deﬁciencies.
BIOLOGICAL DIFFERENCES IN EPA, DHA, ANDDPA
Omega-3 fatty acid treatment lowers the TG level by
both reducing hepatic TG secretion and enhancing
the rate of TG clearance from the circulation. ApoC3
appears to play an important role in hyper-
triglyceridemia pathogenesis, particularly with re-
gard to inhibiting lipoprotein lipase and hepatic
lipase, which slows TG hydrolysis (133). Apo C3 also
interferes with the TGRL interactions with hepatic
apoB/E receptors, slowing removal of these particles
from circulation (134). ApoC3 is regulated by the he-
patic nuclear factor-4 alpha, forkhead box O tran-
scription factor O1, and carbohydrate response
element–binding protein in response to insulin
(135). Increased apoC3 synthesis may represent a
compensatory mechanism to reduce TGRL catabolism
and uptake by hepatic receptors in an attempt to
cope with a large inﬂux of substrates for TG produc-
tion. The effect of omega-3 fatty acids on apoC3, un-
like that of ﬁbrates, is independent of PPAR-alpha
(136). Both EPA and DHA down-regulate SREBP-1c,
the transcription factor that controls lipogenesis.
EPA is a more potent agonist of PPAR-alpha than
DHA, whereas DHA appears to regulate hepatic nu-
clear factor-4 alpha, forkhead box O transcription
factor O1, and carbohydrate response element–binding
protein (137).
The severity of hypertriglyceridemia is typically
associated with the apoC3 level. Fish oil containing
a complex mixture of omega-3 fatty acids lowered
apoC3 in patients with hypertriglyceridemia
(138). This is of potential clinical importance, because
elevated apoC3 levels associated with VLDL þ LDL
particles were independent predictors of CVD
event risk, and loss-of-function apoC3 gene poly-
morphisms were associated with reduced CVD event
risk (110,111) (Figure 2B).
EMERGING THERAPIES FOR MANAGEMENT
OF HYPERTRIGLYCERIDEMIA
A number of new therapies to address the challenges
and unmet needs of patients with high TG and mixeddyslipidemia are being developed. Some are new
formulations or improved delivery systems of pre-
existing drugs, whereas others target new mecha-
nisms for TGRL metabolism and hypertriglyceridemia
management. Cell-penetrating peptides or linker
technologies combining niacin and omega-3, PCSK9
inhibitors, apoC3-antisense, DGAT1 inhibitors, MTP
inhibitors, peptide mimetics, and LPL gene replace-
ment therapy represent the diversity of mechanisms
and targets for management of TGRL and severe
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fasting TG concentration in different proportions:
some are more effective on post-prandial lipid
metabolism and the exogenous (chylomicron) path-
way, and others are more effective on the endoge-
nous pathway, on liver fat management (including
nonalcoholic fatty liver disease and insulin resis-
tance), or on fat metabolism in adipocytes and
peripheral tissues (including lipodystrophies).
Cell-penetrating peptides represent a new mecha-
nism of drug delivery. When conjugated to macro-
molecules or when used at low concentrations,
cell-penetrating peptides enter cells via the endo-
cytic pathway. CAT-2003, a novel niacin and EPA
conjugate, is currently in a phase II clinical trial for
treatment of severe hypertriglyceridemia of different
causes (139). In pre-clinical studies, CAT-2003 syner-
gistically reduced TG superior to niacin and EPA,
individually or combined. CAT-2003 inhibits the
transcription factor SREBP in vitro and in vivo (140),
resulting in reduced PCSK9 expression. SiRNA inhi-
bition of PCSK9 gene expression reduces production
and assembly of multiple cholesterol biosynthetic
enzymes in the cellular SREBP2 pathway, as well as of
several enzymes involved in intestinal TGRL synthe-
sis and assembly (15).
ISIS-APOCIIIRx is a second-generation 20-O-(2-
methoxyethyl) modiﬁed antisense inhibitor of apoC3
synthesis. ISIS-APOCIIIRx selectively inhibits hepatic
apoC3 protein synthesis by binding to a small
sequence of apoC3 mRNA to elicit its degradation by
RNase H1, an endogenous ribonuclease expressed
ubiquitously in mammalian cells. In phase 2 studies,
ISIS-APOCIIIRx was highly effective in lowering
apoC3, fasting plasma TG, and non–HDL-C in patients
with elevated VLDL-TG or chylomicron-TG due to a
variety of conditions, including familial chylomicro-
nemia due to lipoprotein lipase deﬁciency (LPLD),
suggesting that apoC3 might play a key role in a non-
LPL–dependent TGRL metabolic pathway (141).
Because hepatic apoC3 potentially promotes clear-
ance of excess hepatic TG, ASO inhibition of apoC3
could theoretically exacerbate hepatic lipid accumu-
lation (142,143).
Lomitapide is an MTP inhibitor that interferes with
apoB-containing lipoprotein assembly in the apoB100
and apoB48 pathways, thus reducing both chylomi-
cron and VLDL secretion. It is currently available for
the management of homozygous FH, and has been
used long-term (>13 years) to treat a single patient
with extremely severe hypertriglyceridemia due to
LPLD (144). Lomitapide 40-mg daily eliminated
chronic abdominal pain and prevented pancreatitis;
however, the fatty liver present before treatmentprogressed to steatohepatitis and ﬁbrosis after 12 to
13 years.
DGAT1 catalyzes the ﬁnal step of TG synthesis and
is highly expressed in the gut wall, where it plays a
key role in dietary fat absorption as chylomicron-TG
(145,146). DGAT1 and DGAT2 are also required for
LD formation in adipocytes, they are active in seba-
ceous glands, and their dysregulation contributes to
the imbalance between lipid supply and demand
and nonalcoholic fatty liver disease development
(147,148). Pradigastat (formerly LCQ908), a selective
DGAT1 inhibitor, is being evaluated for treatment of
familial chylomicronemia (149). In healthy human
volunteers, pradigastat decreases post-prandial
chylomicron particle numbers and prevents post-
prandial hypertriglyceridemia (150). Gastrointestinal
events such as diarrhea, abdominal pain, and nausea
are the most commonly reported adverse events, and
are related to dose and dietary fat content.
AAV1-LPLS447X gene replacement therapy (alipo-
gene tiparvovec) was developed for treatment of
familial chylomicronemia due to LPLD (151–155).
LPL gene therapy adds extra copies of the gene
encoding a functionally potent enzyme to muscle
tissue of affected patients, speciﬁcally homozygotes
or compound heterozygotes with documented null,
LPLD-causing LPL gene mutations. In pivotal clinical
trials, intramuscular administration of alipogene
tiparvovec was generally well tolerated and associ-
ated with signs of clinical improvement and reduc-
tion in overall pancreatitis incidence up to 5 years
after administration (155).
CONCLUSIONS
Elevated fasting and nonfasting TG levels were asso-
ciated with incident CVD events in multiple studies;
however, they also accompany a multitude of bio-
markers (lipoproteins, inﬂammatory mediators and
proteins, and hemostatic measures) and CVD-
associated conditions, including type 2 diabetes mel-
litus. Recent clinical trials failed to demonstrate a
reduction in CVD events in statin-treated patients also
treated with ﬁbrates and niacin, challenging elevated
TG as an independent risk factor. However, clinical
trials with ﬁbrates demonstrated risk reduction in
subgroups with fasting TG $200 mg/dl, particularly
those with low HDL-C, indicating a threshold effect
that should mandate future TG-lowering therapy
trials.
Our understanding of TG-associated CVD risk
evolved with the recognition that TG is just 1
component of a vastly heterogeneous TGRL pool.
Genetic studies demonstrate a causal relationship of
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2537certain TGRL components and TGRL synthetic and
metabolic pathways with atherosclerotic CVD events.
Speciﬁc genetic mechanisms that increase plasma
TGRL and affect CVD include loss of LPL function,
loss of APOA5 function, gain of ANGPTL4 function,
and gain of APOC3 function.
Importantly, these genetic studies identiﬁed spe-
ciﬁc targets in the causal pathway that may be can-
didates for pharmacological intervention. Ongoing
clinical trials targeting causal pathways in TGRLmetabolism should clarify the role of TGRLs and
CVD. In the interim, we advocate the use of avai-
lable TG-lowering therapy for prevention of acute
pancreatitis.
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